These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23008470)

  • 21. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Raj SR; Mitchell LB; Sheldon RS
    N Engl J Med; 2000 Jul; 343(1):68-9. PubMed ID: 10896549
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of hypertrophic cardiomyopathy.
    Penas-Lado M; Barriales-Villa R; Monserrat L
    Circulation; 2003 Apr; 107(16):e110; auhor reply e110. PubMed ID: 12719296
    [No Abstract]   [Full Text] [Related]  

  • 23. A comprehensive approach to management of ventricular arrhythmias.
    Kusumoto F
    Cardiol Clin; 2008 Aug; 26(3):481-96, vii. PubMed ID: 18538192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
    Cotiga D; Ehlert F; Sherrid M
    Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of the implantable cardioverter-defibrillator in secondary prevention of sudden death in hypertrophic cardiomyopathy patients].
    Primo J; Geelen P; Brugada J; Lorga Filho A; Mont L; Wellens F; Valentino M; Brugada P
    Rev Port Cardiol; 1998 Oct; 17(10):783-7. PubMed ID: 9865087
    [No Abstract]   [Full Text] [Related]  

  • 26. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
    Maron BJ; Spirito P
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.
    Maron BJ; Estes NA; Maron MS; Almquist AK; Link MS; Udelson JE
    Circulation; 2003 Jun; 107(23):2872-5. PubMed ID: 12814983
    [No Abstract]   [Full Text] [Related]  

  • 29. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: is it safe?
    Veselka J
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):520-1; author reply 522. PubMed ID: 19496117
    [No Abstract]   [Full Text] [Related]  

  • 30. Asystole and scarring of the interventricular septum in hypertrophic cardiomyopathy.
    Foley PW; Frenneaux MP; Leyva F
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):349-51. PubMed ID: 19430348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy.
    Almquist AK; Hanna CA; Haas TS; Maron BJ
    J Cardiovasc Electrophysiol; 2008 Mar; 19(3):319-22. PubMed ID: 17764447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of a dual chamber implantable cardioverter-defibrillator].
    Kazmierczak J; Tavernier R; De Sutter J; Jordaens L
    Pol Merkur Lekarski; 2000 Aug; 9(50):522-6. PubMed ID: 11081315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained right ventricular tachycardia originating close to defibrillator lead tip in hypertrophic cardiomyopathy.
    Casella M; Dello Russo A; Pelargonio G; Tondo C
    J Cardiovasc Electrophysiol; 2007 Sep; 18(9):994-7. PubMed ID: 17343718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sudden death and obstructive hypertrophic cardiomyopathy].
    Baille N
    Ann Cardiol Angeiol (Paris); 1985 Mar; 34(3):155-60. PubMed ID: 3890678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can sudden cardiac death be prevented?
    Maron BJ
    Cardiovasc Pathol; 2010; 19(6):329-35. PubMed ID: 20378375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable defibrillators in hypertrophic cardiomyopathy.
    Grace A
    Heart; 2009 May; 95(9):695-6. PubMed ID: 19282312
    [No Abstract]   [Full Text] [Related]  

  • 39. Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk.
    Kamath GS; Mittal S; Sherrid MV
    Anadolu Kardiyol Derg; 2009 Dec; 9 Suppl 2():32-40. PubMed ID: 20089485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm and sustained ventricular tachycardia: a case report].
    Kono K; Higashi T; Hara K; Mori S; Ito I; Shinbo G; Anzai R; Yagi H; Tamano K; Horinaka S; Matsuoka H
    J Cardiol; 2001 Dec; 38(6):343-9. PubMed ID: 11806092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.